Year 2018 / Volume 110 / Number 9
Original
Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA

557-563

DOI: 10.17235/reed.2018.5533/2018

Weijia Duan, Xiaojuan Ou, Xiaoming Wang, Yu Wang, Xinyan Zhao, Qianyi Wang, Xiaoning Wu, Wei Zhang, Hong Ma, Hong You, Jidong Jia,

Abstract
Background: primary biliary cholangitis (PBC) patients with a suboptimal response to ursodeoxycholic acid (UDCA) have a significantly worse survival rate. Fenofibrate has been shown to improve the short-term biochemical response in this group of patients. However, there is limited data available on the safety and efficacy of its long-term use, especially in patients with cirrhosis. Methods:in this retrospective cohort study, fenofibrate was given to PBC patients with a suboptimal response to at least 12 months of UDCA (13-15 mg/kg/d) therapy. Biochemistry data, GLOBE score and UK-PBC risk score at baseline and at different time points of treatment were compared. The safety profiles were also compared between cirrhotic and non-cirrhotic patient groups. Results:fenofibrate (200 mg/day) was given to 39 PBC patients with a suboptimal response to UDCA (15 cirrhotic and 24 non-cirrhotic patients). In the 26 patients who completed more than one year of combination therapy, the alkaline phosphatase (ALP) levels were 215 (185, 326) U/l, 122 (110, 202) U/l, 128 (106, 194) U/l, 124 (100, 181) U/l and 120 (82, 168) U/l, at baseline, three months, six months, 12 months and 24 months, respectively. All p values were < 0.01 when compared to baseline values. After two years of combination therapy, the UK-PBC risk score and GLOBE score did not significantly improve. The overall rates of adverse events were not significantly different between the cirrhotic and non-cirrhotic group. The elevation of liver enzymes was the most frequent side effect (n = 7), leading to a discontinuation in four patients. Furthermore, after two years of combination therapy, the serum creatinine levels and estimated glomerular filtration rates (eGFR) were significantly worse in both groups. Conclusion: fenofibrate add-on therapy could improve ALP and γ-GT levels in both non-cirrhotic and cirrhotic PBC patients with a suboptimal response to UDCA. However, patients need to be monitored carefully for a potential liver injury and nephrotoxicity.
Share Button
New comment
Comments
No comments for this article
References
1.Rudic, JS, G Poropat, MN Krstic, et al.Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev2012; 12: CD000551.
1. Rudic JS, Poropat G, Krstic MN, et al.Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev2012; 12: CD000551.
2. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology2006;130:715-20.
3. Corpechot C, Abenavoli L, Rabahi N, et al.Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology2008;48:871-7.
4. Kuiper EM, Hansen BE, de Vries RA, et al.Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology2009;136:1281-7.
5. Zhang, LN, Shi TY, Shi XH, et al.Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology2013;58:264-72.
6. Ohira H, Sato Y, Ueno T, et al.Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol2002;97:2147-9.
7. Dohmen K, Mizuta T, Nakamuta M, et al.Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol2004;10:894-8.
8. Walker LJ, Newton J, Jones DE, et al.Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology2009;49:337-8.
9. Liberopoulos EN, Florentin M, Elisaf MS, et al.Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med J2010;4:120-6.
10. Levy C, Peter JA, Nelson DR, et al.Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment PharmacolTher2011;33:235-42.
11. Han XF,. Wang QX, Liu Y, et al.Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. J Dig Dis2012;13:219-24.
12. Lindor KD, Gershwin ME, Poupon R, et al.Primary biliary cirrhosis. Hepatology2009;50: 291-308.
13. Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014;147:1338-49.
14. Lens S, Leoz M, Nazal L, et al. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int2014;34:197-203.
15. Suk KT, Baik SK, Yoon JH, et al.Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol2012;18:1-21.
16. Pannu N, Nadim MK.An overview of drug-induced acute kidney injury.Crit Care Med2008;36(4 Suppl): S216-23.
17. Schetz M, Dasta J, Goldstein S, et al.Drug-induced acute kidney injury.CurrOpinCrit Care2005;11:555-65.
18. Mehta RL, Kellum JA, Shah SV, et al.Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.CritCare 2007;11:R31.
19. Levey AS, Stevens LA, Schmid CH, et al.A new equation to estimate glomerular filtration rate. Ann Intern Med2009;150: 604-12.
20. Levey AS, Coresh J, Greene T, et al.Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values.ClinChem2007;53:766-72.
21. Aithal GP, Watkins PB, Andrade RJ,et al.Case Definition and Phenotype Standardization in Drug-Induced liver injury. Clin Pharmacol Ther. 2011;89:806-15.
22. Hegade VS, Khanna A, Walker LJ, et al.Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score. Dig Dis Sci2016; 61:3037-44.
23. Cheung AC, Lapointe-Shaw L, Kowgier M, et al.Combinedursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment PharmacolTher2016;43:283-93.
24. Yang F, Yang Y, Wang Q, et al., The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210. Aliment PharmacolTher2017;45: 733-43.
25. Attridge RL, Linn WD, Ryan L, et al. Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. J ClinLipidol2012;6:19-26.
26. Ansquer JC, Dalton RN, Causse E, et al.Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis2008;51:904-13.
27. Zhao YY, Weir MA, Manno M, et al.New fibrate use and acute renal outcomes in elderly adults: a population-based study. Ann Intern Med2012;156:560-9.
28. Attridge RL, Frei CR, Ryan L, et al.Fenofibrate-associated nephrotoxicity: a review of current evidence. Am J Health Syst Pharm2013;70:1219-25.
29. Bonds DE, Craven TE, Buse J, et al.Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience.Diabetologia2012;55:1641-50.
30. Mychaleckyj JC, Craven T, Nayak U, et al.Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care2012;35:1008-14.
Related articles

Editorial

Cases of liver disease lost in the health system: a call to action

DOI: 10.17235/reed.2021.8316/2021

Review

Practical management of primary biliary cholangitis

DOI: 10.17235/reed.2021.8219/2021

Review

Risk stratification and treatment of primary biliary cholangitis

DOI: 10.17235/reed.2018.5662/2018

Case Report

The clinical extremes of autoimmune cholangitis

DOI: 10.17235/reed.2017.4167/2015

Citation tools
Duan W, Ou X, Wang X, Wang Y, Zhao X, Wang Q, et all. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA. 5533/2018


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1322 visits.
This article has been downloaded 468 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 11/02/2018

Accepted: 02/04/2018

Online First: 09/05/2018

Published: 31/08/2018

Article revision time: 46 days

Article Online First time: 87 days

Article editing time: 201 days


Share
This article has been rated by 2 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology